|
Milan Gagic
Senior Advisor, New Organisms, Environmental Protection Authority - Te Mana Rauhī Taiao, NZ Dr. Milan Gagic holds a PhD in biotechnology from the University of Auckland, and MSc in biochemistry and human genetics from the Otago University. He has worked for more than 20 years as a research scientist and project leader at Christchurch School of Medicine and AgResearch, Grasslands. His main areas of interests were related to the plant improvement through the use of modern biotechnology tools. He was leading projects looking at the plant and fungal symbiotic relationship, focusing on their role in ruminant health and digestion, in the context of methane and CO2 emission. Milan currently works as a senior advisor in the New Organism team focusing on both, medical and agricultural biotechnology related applications and assessments.
|
|
Use of GMOs in Therapeutic Products - the EPA Perspective
The Environmental Protection Authority (EPA) is a Crown agent and national regulator, committed to protect people and the environment. The EPA regulate human activities that impact the environment and people of Aotearoa New Zealand. As stewards of the natural environment, and in our role supporting kaitiakitanga, we regulate the future environment through our work and decisions undertaken today. In this talk I will give an overview of the EPA responsibilities, focusing on the activities of the New Organisms group within the EPA.
Novel approaches using viral vectors especially in the area of cancer treatment often require obtaining necessary approvals from the EPA before the clinical trial commencement or therapy registration. Depending on the type and nature of the therapy and the viral vectors used, there are several options available to the applicants. This talk will discuss issues and regulations relevant to such applications from the EPA perspective. I will examine available pathways, including the information needed for us to make an assessment and approve the release of such a therapy.
The Environmental Protection Authority (EPA) is a Crown agent and national regulator, committed to protect people and the environment. The EPA regulate human activities that impact the environment and people of Aotearoa New Zealand. As stewards of the natural environment, and in our role supporting kaitiakitanga, we regulate the future environment through our work and decisions undertaken today. In this talk I will give an overview of the EPA responsibilities, focusing on the activities of the New Organisms group within the EPA.
Novel approaches using viral vectors especially in the area of cancer treatment often require obtaining necessary approvals from the EPA before the clinical trial commencement or therapy registration. Depending on the type and nature of the therapy and the viral vectors used, there are several options available to the applicants. This talk will discuss issues and regulations relevant to such applications from the EPA perspective. I will examine available pathways, including the information needed for us to make an assessment and approve the release of such a therapy.
